Global Blood Therapeutics Inc (GBT) Shares Bought by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC raised its holdings in Global Blood Therapeutics Inc (NASDAQ:GBT) by 31.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,097 shares of the company’s stock after purchasing an additional 5,516 shares during the period. MetLife Investment Advisors LLC’s holdings in Global Blood Therapeutics were worth $1,044,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. California State Teachers Retirement System lifted its position in shares of Global Blood Therapeutics by 1.9% in the first quarter. California State Teachers Retirement System now owns 59,314 shares of the company’s stock valued at $2,865,000 after acquiring an additional 1,115 shares in the last quarter. First Allied Advisory Services Inc. lifted its position in shares of Global Blood Therapeutics by 21.4% in the second quarter. First Allied Advisory Services Inc. now owns 7,950 shares of the company’s stock valued at $359,000 after acquiring an additional 1,400 shares in the last quarter. Great West Life Assurance Co. Can lifted its position in shares of Global Blood Therapeutics by 42.0% in the second quarter. Great West Life Assurance Co. Can now owns 4,969 shares of the company’s stock valued at $224,000 after acquiring an additional 1,469 shares in the last quarter. Sei Investments Co. lifted its position in shares of Global Blood Therapeutics by 12.1% in the second quarter. Sei Investments Co. now owns 13,850 shares of the company’s stock valued at $626,000 after acquiring an additional 1,499 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its position in shares of Global Blood Therapeutics by 4.4% in the first quarter. New York State Common Retirement Fund now owns 47,758 shares of the company’s stock valued at $2,307,000 after acquiring an additional 2,000 shares in the last quarter. 98.79% of the stock is currently owned by institutional investors.

In other Global Blood Therapeutics news, Director Deval L. Patrick sold 42,379 shares of Global Blood Therapeutics stock in a transaction on Friday, July 6th. The stock was sold at an average price of $43.40, for a total value of $1,839,248.60. Following the sale, the director now owns 15,000 shares in the company, valued at $651,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lesley Ann Calhoun sold 2,004 shares of Global Blood Therapeutics stock in a transaction on Friday, August 17th. The shares were sold at an average price of $49.89, for a total value of $99,979.56. Following the completion of the sale, the insider now owns 1,342 shares in the company, valued at approximately $66,952.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,678 shares of company stock worth $2,128,844. 4.40% of the stock is currently owned by company insiders.

Shares of Global Blood Therapeutics stock opened at $39.10 on Thursday. Global Blood Therapeutics Inc has a one year low of $28.00 and a one year high of $68.05.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Thursday, August 2nd. The company reported ($0.78) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.09. During the same period in the previous year, the company posted ($0.55) EPS. equities research analysts anticipate that Global Blood Therapeutics Inc will post -3.38 earnings per share for the current year.

Several equities analysts have recently weighed in on GBT shares. BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 19th. HC Wainwright set a $125.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a research report on Friday, August 10th. Nomura raised their target price on Global Blood Therapeutics from $91.00 to $109.00 and gave the company a “buy” rating in a research report on Thursday, June 28th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $96.00 target price on shares of Global Blood Therapeutics in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $80.53.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

See Also: Outstanding Shares

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply